af-001
/ Alpha Fusion
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 31, 2025
Alpha Fusion…announced the initiation of a company-sponsored Phase I clinical trial (jRCT2031250472) of the alpha-emitting radiopharmaceutical af-001, which contains [
211
At]NaAt as its active pharmaceutical ingredient, in patients with differentiated thyroid cancer (papillary and follicular carcinoma)
(PRNewswire-Asia)
- "This clinical trial is designed based on the results of an investigator-initiated Phase I study conducted at The University of Osaka, and consists of Part Ia and Part Ib."
Trial status • Differentiated Thyroid Carcinoma • Thyroid Gland Follicular Carcinoma • Thyroid Gland Papillary Carcinoma
1 to 1
Of
1
Go to page
1